title: The "cyclic" regimen of low-dose doxycycline for adult periodontitis: a preliminary study.
abstract: Specially-formulated low-dose doxycycline (LDD) regimens have been found to reduce collagenase activity in the gingival tissues and crevicular fluid (GCF) of adult periodontitis subjects in short-term studies. In the current, double-blind, placebo-controlled study, adult periodontitis patients were administered for 6 months a "cyclical" regimen of either LDD or placebo capsules; and various clinical parameters of periodontal disease severity, and both collagenase activity and degradation of the serum protein, alpha 1-PI, in the GCF were measured at different time periods. No significant differences between the LDD- and placebo-treated groups were observed for plaque index and gingival index. However, attachment levels, probing depth, and GCF collagenase activity and alpha 1-PI degradation were all beneficially and significantly (P < 0.05) affected by the drug regimen. We propose: 1) that LDD inhibits tissue destruction in the absence of either antimicrobial or significant anti-inflammatory efficacy; and 2) that long-term LDD could be a useful adjunct to instrumentation therapy in the management of the adult periodontitis patient.
authors.affiliation: Department of Periodontology, West Virginia University, Morgantown, USA.
authors.forename: R J
authors.initials: RJ
authors.lastname: Crout
authors.forename: H M
authors.initials: HM
authors.lastname: Lee
authors.forename: K
authors.initials: K
authors.lastname: Schroeder
authors.forename: H
authors.initials: H
authors.lastname: Crout
authors.forename: N S
authors.initials: NS
authors.lastname: Ramamurthy
authors.forename: M
authors.initials: M
authors.lastname: Wiener
authors.forename: L M
authors.initials: LM
authors.lastname: Golub
mesh_terms: D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D004311:Double-Blind Method; D004318:Doxycycline / Q000008:administration & dosage* / Q000627:therapeutic use; D004334:Drug Administration Schedule; D005260:Female; D005883:Gingival Crevicular Fluid / Q000201:enzymology; D006801:Humans; D008297:Male; D061965:Matrix Metalloproteinase Inhibitors; D008875:Middle Aged; D010196:Pancreatic Elastase / Q000378:metabolism; D017622:Periodontal Attachment Loss / Q000517:prevention & control; D010518:Periodontitis / Q000188:drug therapy* / Q000201:enzymology; D015842:Serine Proteinase Inhibitors / Q000378:metabolism; D000515:alpha 1-Antitrypsin / Q000378:metabolism
chemical_list: D000900:Anti-Bacterial Agents; D061965:Matrix Metalloproteinase Inhibitors; D015842:Serine Proteinase Inhibitors; D000515:alpha 1-Antitrypsin; D010196:Pancreatic Elastase; D004318:Doxycycline